MedTrace Logo

Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp

NCT05105139 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2022-04-13

No results posted yet for this study

Summary

Observational, descriptive, retrospective, multicenter study to evaluate the safety of the treatment with Sebryl® and / or Sebryl Plus® in the management of seborrheic dermatitis and psoriasis of the scalp in routine medical practice.

Conditions

  • Seborrheic Dermatitis
  • Psoriasis of Scalp

Interventions

OTHER

Allantoin/ Coal Tar/ Clioquinol

Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 5.0 g/ Clioquinol 3.0 g Administration way: For scalp use

OTHER

Allantoin/ Coal Tar/ Clioquinol/ Triclosan

Pharmaceutical Form: Shampoo Dosage: Allantoin 0.2 g/ Coal Tar 3.0 g/ Clioquinol 3.0 g/ Triclosan 0.3 g. Administration way: For scalp us

Sponsors & Collaborators

  • Laboratorios Silanes S.A. de C.V.

    lead INDUSTRY

Principal Investigators

  • María E Morales Barrera, M.D · Independent consultant

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-29
Primary Completion
2022-02-15
Completion
2022-02-25

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05105139 on ClinicalTrials.gov